ImmunoGen, Inc. Announces Conference Call to Discuss Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 28, 2016, to discuss ImmunoGen’s financial results for the three-month period and fiscal year ended September 30, 2016. Management also will provide a brief update on the business.
To access the live call by phone, dial 913-312-0710; the conference ID
is 4316729. The call also may be accessed through the Investors section
of the Company’s website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through November 11, 2016.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen’s lead product candidate, mirvetuximab soravtansine, is being
advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian
cancer, and is in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen’s ADC technology is used in Roche’s
marketed product, Kadcyla^®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by partners
Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.
Kadcyla^® is a registered trademark of Genentech, a member of
the Roche Group.